E2511

E2511
Clinical data
Other namesE-2511
Routes of
administration		Oral
Drug classTropomyosin receptor kinase A (TrkA) positive allosteric modulator
Pharmacokinetic data
Elimination half-life3.2 hours

E2511, or E-2511, is a selective biased tropomyosin receptor kinase A (TrkA) positive allosteric modulator which is under development for the treatment of Alzheimer's disease. It is taken orally. The drug has been found to increase cholinergic signaling in preclinical research. The elimination half-life of E2511 is 3.2 hours in humans. E2511 is under development by Eisai. As of September 2024, it is in phase 1 clinical trials for Alzheimer's disease. A phase 1 clinical trial has been completed. The chemical structure of E2511 does not yet appear to have been disclosed.

See also

References

  1. 1 2 3 4 5 6 7 "E 2511". AdisInsight. 26 September 2024. Retrieved 10 June 2026.
  2. 1 2 3 4 5 6 7 "E2511". ALZFORUM. 9 November 2023. Retrieved 10 June 2026.
  3. 1 2 3 4 5 Forsell P, Parrado Fernández C, Nilsson B, Sandin J, Nordvall G, Segerdahl M (July 2024). "Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer's Disease". Pharmaceuticals. 17 (8). Basel, Switzerland: 997. doi:10.3390/ph17080997. PMC 11357672. PMID 39204102.
  4. 1 2 3 Aceves P, Hall N, Dayal S, Yagi T, Chang J, Mikamoto M, et al. (2023). "First-in-Human (FIH), Single- and Multiple-Ascending-Dose (SAD/MAD) studies in healthy subjects of E2511, a novel tropomyosin receptor kinase a (TrkA) positive allosteric modulator (PAM)". Alzheimer's & Dementia. 19 (S7) e066208. doi:10.1002/alz.066208. ISSN 1552-5260.
  5. ↑ Enkavi G (February 2026). "Molecular determinants of signal transduction in tropomyosin receptor kinases". FEBS Open Bio. 16 (2): 252–267. doi:10.1002/2211-5463.70135. PMC 12871558. PMID 41053984.
  6. ↑ Nordvall G, Forsell P, Sandin J (October 2022). "Neurotrophin-targeted therapeutics: A gateway to cognition and more?". Drug Discovery Today. 27 (10) 103318. doi:10.1016/j.drudis.2022.07.003. PMID 35850433.
  7. ↑ Tomioka T, Hiramatsu N, Moriyama Y, Kosasa T (2023). "E2511, a novel small compound TrkA biased positive allosteric modulator, reinnervates cholinergic neuron and activates cholinergic functions in non-clinical studies". Alzheimer's & Dementia. 19 (S7) e062590. doi:10.1002/alz.062590. ISSN 1552-5260.
  8. ↑ Tomioka T, Moriyama Y, Hiramatsu N, Kosasa T, Kondo K, Wakita H (2021). "E2511, a novel small compound TrkA allosteric modulator, induces a specific trophic signaling via direct binding to TrkA, and can reverse the loss of choline acetyltransferase (ChAT) positive neurons in transgenic models of AD". Alzheimer's & Dementia. 17 (S9) e051985. doi:10.1002/alz.051985. ISSN 1552-5260.